VRTX VERTEX PHARMACEUTICALS INC Product Launches 8-K Filing 2024 - FDA Approval Vertex Pharmaceuticals received FDA approval for ALYFTREK, a cystic fibrosis treatment, priced at $370,269 annually.Get access to all SEC 8-K filings of the VERTEX PHARMACEUTICALS INC